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The Influence of Enrollment Criteria on Recruitment
and Outcome Distribution in Traumatic Brain Injury Studies:
Results from the Impact Study
Bob Roozenbeek,1,2 Andrew I.R. Maas,2,3 Anthony Marmarou,4 Isabella Butcher,5 Hester F. Lingsma,1
Juan Lu,4 Gillian S. McHugh,5 Gordon D. Murray,5 Ewout W. Steyerberg,1 and The IMPACT* Study Group
Abstract
Substantial heterogeneity exists among patients who suffer from traumatic brain injury (TBI). Strict enrollment
criteria may diminish heterogeneity in randomized controlled trials (RCTs), but will also decrease recruitment
and may affect the outcome distribution. The aim of this study was to investigate the influences of commonly
used enrollment criteria for RCTs in TBI on potential recruitment and on outcome distribution. We used indi-
vidual patient data from the International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT)
database, including six therapeutic phase III RCTs (n¼ 5816) and three surveys (n¼ 2217) in TBI. The primary
outcome was the Glasgow Outcome Scale (GOS) at 6 months after injury, which we dichotomized as favorable=
unfavorable. We investigated the influences of commonly used enrollment criteria on recruitment and outcome
distribution: time window between injury and admission to study hospital 8 h; age at injury 65 years; 1
reactive pupil; motor score> 1; Glasgow Coma Scale 8. Application of all enrollment criteria resulted in a large
reduction of recruitment in both the surveys (up to 65%) and the RCTs (up to 41%). Among the remaining
patients, fewer had an unfavorable outcome in both the surveys (original, 60%; remaining, 44%) and the RCTs
(original, 43%; remaining, 38%). Applying these enrollment criteria to patients from the surveys resulted in an
outcome distribution that approximated the outcome observed in the RCTs. The use of strict enrollment criteria
leads to substantial reductions in the recruitment of RCTs in TBI. The outcome in TBI studies depends strongly
on the enrollment criteria.
Key words: enrollment criteria; heterogeneity; outcome distribution; randomized controlled trial; recruitment;
traumatic brain injury
Introduction
Traumatic brain injury (TBI) represents a serious healthproblem worldwide, posing high costs to society. Much
research is undertaken to improve outcome after TBI. Com-
paring outcome between different series of TBI patients and
demonstrating efficacy of new approaches in randomized
clinical trials (RCTs) is notoriously difficult due to the inher-
ent heterogeneity of TBI populations (Maas et al., 1999). Het-
erogeneity in terms of type and severity of injury, as well as
in terms of prognostic risk, may cause imbalances between
treatment groups and dilute treatment effects.
Imbalances in baseline characteristics between treatment
groups have been reported in some RCTs (Marshall et al.,
1998). Such imbalances may be prevented by block random-
ization (Bullock, 2002), stratified randomization (Bullock,
2002; Choi and Bullock, 2001; Maas et al., 1999), and mini-
mization. We may achieve similar numbers of patients in
each arm of the trial by random allocation in blocks (‘‘block
randomization’’). Stratified randomization may be used to
ensure that equal numbers will be allocated to each arm with
a characteristic thought to affect prognosis. Furthermore,
minimization may be used to ensure balance between trial
arms for several patient factors. The first patient is truly
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randomly allocated; for each subsequent patient, the treat-
ment allocation is identified, which minimizes the imbalance
between groups at that time. Approaches for dealing with the
heterogeneity in the analysis phase (e.g., covariate adjust-
ment) have also been employed in TBI trials (Herna´ndez et al.,
2006).
Heterogeneity amongst the population under study may
also be reduced by using strict enrollment criteria. Enrollment
criteria aim to select patients that are most likely to benefit
from the studied treatment, both from a mechanistic and
prognostic perspective (Maas et al., 1999; Machado et al.,
1999; Narayan et al., 2002). Threemain goals are aimed for: (1)
exclusion of patients with a very good or very bad prognosis,
because one may expect that these patients will do well
without any treatment or will do poorly no matter what
treatment is given; (2) inclusion of patients who are likely to
benefit from the treatment, because of the pathophysiologic
background of the injury and the studied treatment; (3)
reaching a distribution of approximately 50% of patients with
a favorable outcome and 50% of patients with an unfavorable
outcome in the study population, to increase statistical power
for the detection of a true treatment effect.
Machado et al. (1999) have demonstrated that targeting a
clinical trial to patients with an intermediate prognostic risk
would permit a potential reduction in sample size of ap-
proximately 30%. The disadvantage of this approach, how-
ever, is that it may substantially reduce recruitment.
The objective of this study is to investigate the influences of
common enrollment criteria on the potential recruitment and
on the outcome distribution of RCTs in TBI.
Methods
Study population
We used individual patient data from the International
Mission on Prognosis and Analysis of Clinical Trials in TBI
(IMPACT) database. This database contains data of patients
with moderate (Glasgow Coma Scale [GCS], 9–12) and severe
(GCS 8) TBI from eight RCTs and three surveys conducted
between 1984 and 1996. IMPACT links researchers in Bel-
gium, the Netherlands, the United Kingdom, and the United
States in a project addressing methodological problems in
design and analysis of RCTs in TBI. Details of the different
studies and data management of the IMPACT database have
been described previously (Marmarou et al., 2007). The pri-
mary outcomemeasurement was the GlasgowOutcome Scale
(GOS) at 6 months after injury. For our analyses, we dichot-
omized the GOS into unfavorable (GOS 1–3) versus favorable
outcome (GOS 4–5). We selected patients over 14 years of age
at the time of injury. The data from two RCTs (HIT-I and SKB)
were not used in our analysis, because the numbers of patients
in these studies were too small for the purpose of our study.
This resulted in a cohort of 8033 adults: 2217 patients from
surveys and 5816 patients from RCTs.
Selection by enrollment criteria
We investigated the influences of five commonly used en-
rollment criteria for TBI studies: time window between injury
and admission to study hospital 8 h; age at injury 65
years; 1 reactive pupil; motor score> 1; and GCS 8. We
further explored the influence of other cut-off values for time
window (4, 6, and 12 h) and for age (55, 60, and 70
years). The enrollment criteria were applied separately and
simultaneously. The influence on the recruitment was studied
by comparing the original sample sizes to the new sample
sizes with the investigated enrollment criteria applied. The
change in outcome distribution was studied by comparing
unfavorable outcome fractions at 6 months after the injury.
Statistical analysis
Descriptive statistics included medians and percentages.
The software used was SPSS, version 11.0.1 (SPSS Inc., Chi-
cago, IL). Figure 1was producedwith R software version 2.6.0
(The R Foundation, 2007).
Results
The baseline characteristics of the original study population
are summarized in Table 1. These reflect the effects of the
different initial enrollment criteria per study.
Effects of enrollment criteria on recruitment
Effects of enrollment criteria on recruitment were more pro-
nounced in the surveys than in the RCTs, since these had less
stringent initial enrollment criteria (Table 1). When each of the
studied criteria was applied separately in the surveys, ‘‘at least
one reactive pupil’’ led to the largest reduction in recruit-
ment (32%), followed by ‘‘time window< 8h’’ (20%), ‘‘motor
score> 1’’ (18%), ‘‘GCS 8’’ (15%), and ‘‘age at injury 65’’
(12%; Table 2). In the RCTs, the reductions were less (Table 2).
As expected, using shorter time windows led to a greater
reduction of recruitment in both the surveys and the RCTs
(Table 3). In the surveys, the recruitment reduction decreased
gradually with the use of higher maximum ages: 22% (55
years); 17% (60 years); 12% (65 years); and 9% (70 years;
Table 4). The RCTs showed less reduction: 10% (55 years);
5% (60 years); 2% (65 years); and 0% (70 years; Table 4).
Application of all five studied enrollment criteria simulta-
neously led to a mean recruitment reduction of 65% in the
surveys (Table 2, Fig. 1). In the RCTs, the mean reduction of
the recruitment was 41%.
Effects of enrollment criteria on outcome distribution
The application of more stringent enrollment criteria had
profound effects on the outcome distribution (Table 2). Effects
were greatest for age, pupils,motor score, andGCS. In contrast
to all other selection criteria, the GCS criterion mainly ex-
cluded patients with a favorable outcome. Patients excluded
FIG. 1. The influence of the application of the investigated enrollment criteria (time window 8 h; age at injury 65 years;
1 reactive pupil; motor score> 1; GCS 8) on recruitment and outcome distribution in three surveys and six randomized
controlled trials (RCTs) of the International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) database.
For each study, the selected (gray bars) and the excluded patients (black bars) are depicted. The width of the bars indicates
the numbers of selected and excluded patients.
‰
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Table 1. Distribution of Patient Characteristics Across Three Surveys and Six RCTs from the IMPACT Study
Time window
(hours), median
(interquartile range)
Age (years), median
(interquartile range)
Pupillary
reactivity Motor score
GCS, median
(interquartile range)
(1,2) none=extension
(3) abnormal flexion
(1) both pupils pos (4) normal flexion
(2) one pupil pos (5,6) localizes=obeys
(3) both pupils neg (9) untestable=missing
243 (40%)
300 (50%) 74 (12%)
TCDB (n¼ 604) 1.2 (0.8–3.1) 26 (21–40) 55 (9%) 122 (20%) 6 (4–8)
249 (41%) 134 (22%)
31 (5%)
198 (25%)
429 (54%) 37 (5%)
UK4 (n¼ 791) 3.5 (2.0–8.9) 36 (22–55) 115 (15%) 141 (18%) 6 (4–8)
247 (31%) 221 (28%)
194 (25%)
230 (28%)
527 (64%) 55 (7%)
EBIC (n¼ 822) 3.7 (1.5–8.0) 38 (24–59) 87 (11%) 113 (14%) 7 (4–11)
208 (25%) 281 (34%)
143 (17%)
671 (30%)
1256 (57%) 166 (8%)
Total surveys (n¼ 2217) 2.8 (1.2–6.1) 32 (22–53) 257 (12%) 376 (17%) 7 (4–9)
704 (32%) 636 (29%)
368 (16%)
280 (34%)
583 (71%) 92 (11%)
HIT II (n¼ 819) 2.0 (1.0–4.0) 33 (22–49) 101 (12%) 181 (22%) 8 (6–10)
135 (16%) 207 (25%)
59 (7%)
152 (15%)
709 (68%) 132 (13%)
TIUS (n¼ 1041) .7 (0.5–1.2) 30 (23–41) 122 (12%) 300 (29%) 7 (6–10)
210 (20%) 457 (44%)
0 (0%)
141 (13%)
813 (73%) 237 (21%)
TINT (n¼ 1118) 1.2 (0.8–2.1) 30 (21–45) 170 (15%) 327 (29%) 6 (5–7)
135 (12%) 413 (37%)
0 (0%)
655 (43%)
779 (52%) 165 (11%)
PEGSOD (n¼ 1510) 1.1 (0.6–2.2) 27 (20–38) 160 (11%) 334 (22%) 5 (3–7)
571 (38%) 356 (24%)
0 (0%)
55 (13%)
316 (78%) 91 (22%)
SLIN (n¼ 409) No data 28 (21–43) 79 (19%) 127 (31%) 6 (5–7)
14 (3%) 136 (33%)
0 (0%)
264 (29%)
612 (67%) 143 (16%)
SAPHIR (n¼ 919) 2.3 (1.0–4.2) 32 (20–38) 307 (33%) 223 (24%) 6 (5–8)
0 (0%) 286 (31%)
3 (0%)
1547 (27%)
3812 (66%) 860 (15%)
Total RCTs (n¼ 5816) 1.2 (0.7–2.6) 30 (21–43) 939 (16%) 1492 (26%) 7 (5–10)
1065 (18%) 1855 (32%)
62 (1%)
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for a high age, bilaterally unresponsive pupils or an absent
motor score had more unfavorable outcomes. Only modest
effects of different time windows were seen on the outcome
distribution (Table 3).
Combining all enrollment criteria had a pronounced effect
in the outcome distribution, which was most evident in the
surveys, reflecting the greater initial heterogeneity. In the
surveys the percentage of unfavorable outcome prior to ap-
plying the enrollment criteria was 60%, and decreased to 44%
after applying the enrollment criteria, approximating the
outcome distribution observed in the RCTs.
Effects of the application of all enrollment criteria on
the recruitment and ouctome distribution are illustrated in
Figure 1. For example, the first gray bar of Figure 1 shows that
application of all investigated enrollment criteria on the
population of the Traumatic ComaData Bank (TCDB) survey,
resulted in selection of 253 patients, from whom 43% had an
unfavorable outcome. The first black bar depicts 351 excluded
patients from the TCDB population with an unfavorable
proportion of 81%.
Discussion
Our evaluations show substantial effects of enrollment cri-
teria both on potential recruitment and on outcome. The five
studied enrollment criteria led to a joint reduction of recruit-
ment of 65% in the surveys and 41% in the RCTs, and substan-
tially narrowed the differences in outcome between surveys
and RCTs that were initially present. Clearly, effects in indi-
vidual studies varied with the stringency of original criteria.
As a limitation of our study, it must be noticed that we only
focused on the influences of five enrollment criteria applied
separately and simultaneously. We did not investigate any
interactions between the different enrollment criteria. Struc-
tural abnormalities as visualized by computed tomography
(CT) examination are currently commonly used as selection
criterion for enrollment in RCTs, but we did not include these
in our analyses, as the available information was not detailed
enough in all IMPACT studies.
In TBI, Phase III RCTs traditionally aim to target the pop-
ulation that is most likely to benefit from the therapy under
investigation, both from a mechanistic and prognostic per-
spective. Mechanistic targeting is based upon our—often very
poor—potential for identifying patients in whom specific
pathophysiologic mechanisms are active. In prognostic tar-
geting, enrollment criteria aim to obtain a homogeneous
population with respect to expected outcome, excluding those
with either a very poor or very good prognosis. For this rea-
son, most trials have excluded patients over the age of 65, and
patients with an absent motor response or unreactive pupils.
Indeed, our results show a very high rate of unfavorable
outcome in patients excluded for these reasons, indicating
that this approach is appropriate.
Nevertheless, interpretation should be with caution: TBI is
being seen more frequently in elderly patients and, with the
ageing population, the average age of TBI patients is in-
creasing (Maas et al., 2007). Elderly patients with TBI there-
fore represent an important subpopulation. The poor outcome
in elderly patients observed in our series is primarily caused
by severe TBI (GCS 8), and no inference may be made as to
patients with moderate TBI.
With the current frequent use of early sedation, intubation
and neuromuscular blockade, accurate assessment of the
motor scale may be confounded, leading to erroneously re-
cording the motor score as being absent. Likewise, small un-
reactive pupils may be caused by effects of deep sedation.
Consequently, the use of these criteria in isolation may be
hazardous. Taken in combination, however, reliability will be
increased and for this reason we prefer to classify by prog-
nosis. A limited number of admission characteristics can be
used to establish the baseline prognostic risk in individual
patients (Hukkelhoven et al., 2005, 2006).
Machado et al. (1999) have shown that targeting a trial
towards patients with an intermediate prognosis may reduce
the required sample size by 30%. These conclusions were
reached from analyses performed on the European Brain In-
jury Consortium (EBIC) survey. Our results, including also
analysis of the EBIC survey, however, show that the reduc-
Table 4. Numbers of Excluded Patients by Selection on Age at Injury
Original study
population Age 55 Age 60 Age 65 Age 70
Original
enrollment
criteria N
% Unfav
of N
No. of
patients
excluded
% Unfav of
patients
excluded
No. of
patients
excluded
% Unfav
of patients
excluded
No. of
patients
excluded
% Unfav
of patients
excluded
No. of
patients
excluded
% Unfav
of patients
excluded
TCDBa — 604 65 76 95 59 95 41 95 32 97
UK4a — 791 66 192 84 143 85 90 89 63 89
EBICa > 16 yrs 822 51 226 74 172 77 135 79 101 80
Total surveys 2217 60 494 81 374 83 266 85 196 86
HIT IIb 16–70 yrs 819 40 121 64 70 64 35 71 — —
TIUSb 14–65 yrs 1041 38 63 60 31 61 7 100 — —
TINTb 14–65 yrs 1118 41 121 60 57 67 13 69 — —
PEGSODb 15–70 yrs 1510 51 103 80 60 83 32 84 — —
SLINb 16–65 yrs 409 43 29 72 16 81 1 100 — —
SAPHIRb 15–70 yrs 919 41 145 61 85 67 34 82 — —
Total RCTs 5816 43 582 65 319 69 122 80 — —
aSurvey.
bRandomized controlled trial.
1074 ROOZENBEEK ET AL.
tion in recruitment due to more stringent enrollment criteria
may be even higher, thus obviating the potential benefit. This
touches on the debate whether focused, targeted Phase III
trials, or large mega trials (with inherent heterogeneity)
should be preferred in the field of TBI. To date, only one
mega-trial has been reported in TBI (Edwards et al., 2005).
We found that time window is a crucial factor in deter-
mining recruitment, but that little effect exists on the outcome
distribution. Recruitment reductions by time window selec-
tion varied from 38% (4 h) to 15% (12 h) in the surveys. In
the RCTs, there was a variation of 11% (4 h) to <1% (12 h)
in reduction of recruitment.
Determination of the appropriate time window for a study
should preferably be based on knowledge of the patho-
physiologic mechanism targeted, and the time at which this
mechanism may be active. Extrapolating results from exper-
imental studies to the clinical situation may, however, be
difficult. In practice, timewindows are frequently determined
based on ‘‘best guess’’ and the clinical perception as to the time
frame within which a reasonable number of subjects may be
recruited. Our studies show a substantial decline in recruit-
ment when time windows are shortened from 6 to 4 hours,
but less so on comparing a 6 hour time window to 8 hours.
However, these effects of time window on recruitment were
based on the available data in the IMPACT database about the
time of injury and the time of admission to study hospital. In
practice, the actual time windows to study drug administra-
tion are longer, due to organizational and logistical reasons
such as informed consent procedures (Kompanje et al., 2005).
Therefore, our observations are likely to be an underestima-
tion of the actual decrease in recruitment by time window
selection.
We also probably underestimate the actual recruitment
reduction by application of selection criteria because we in-
vestigated the effect of selection criteria on pre-selected study
populations. In the SAPHIR trial, for example, we have
learned from the screening logs that only 19% of the number
of patients initially screened was enrolled in the trial; 81%
was excluded because of not meeting enrollment criteria, in-
ability to obtain informed consent, or logistic reasons (e.g.,
unavailability of study personnel ormedication) (Slieker et al.,
2008).
The profound effect of enrollment criteria on outcome is
perhaps not surprising, but has hitherto been insufficiently
recognized. Enrollment criteria may be deliberately applied
(as in RCTs), but may also inadvertently result from selec-
tive hospital admission policies in different institutions, or be
caused by effects of local trauma organization, outside the
control of investigators. A detailed understanding of such
factors is, in our opinion, a prerequisite for comparing out-
come results between series, originating from different set-
tings or times.
It is remarkable that the application of common enrollment
criteria to surveys resulted in an approximation of outcome
distribution observed in RCTs.
Conclusion
Strict selection with common enrollment criteria leads to
substantial recruitment reductions in TBI studies. The out-
come distribution strongly depends on the enrollment criteria.
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